| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 07/30/2008 | CN100406437C Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these |
| 07/30/2008 | CN100406044C Medicine for treating fracture and injury |
| 07/30/2008 | CN100406020C Solid-state molecular dispersible preparation of pennogenin compound |
| 07/30/2008 | CN100406019C Solid-state molecular dispersible preparation of pennogenin compound |
| 07/30/2008 | CN100406018C A nanometer 'Xue Sai Tong' injection and preparation method thereof |
| 07/29/2008 | US7405051 Method of screening antiplatelet agents |
| 07/29/2008 | US7404952 ATP-binding cassette transporter polypeptide which regulates metabolism of triglycerides; treatment of obesity and eating disorders |
| 07/29/2008 | CA2371857C Gardos channel antagonists |
| 07/29/2008 | CA2352149C Solid lipidic nanospheres suitable to a fast internalization into cells |
| 07/29/2008 | CA2348742C Carbocyclic potassium channel inhibitors |
| 07/29/2008 | CA2346825C Method for production of stroma-free hemoglobin |
| 07/29/2008 | CA2340237C Indwelling heat exchange catheter and method of using same |
| 07/29/2008 | CA2337755C Inhibitors of p38 |
| 07/29/2008 | CA2295628C Stable formulations comprising a nucleotide and a freeze drying additive |
| 07/29/2008 | CA2262997C Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells |
| 07/29/2008 | CA2223702C Therapeutic fragments of von willebrand factor |
| 07/29/2008 | CA2192543C Interleukin-5 specific recombinant antibodies |
| 07/29/2008 | CA2175767C Adhesion receptor antagonists |
| 07/29/2008 | CA2141842C Novel glycoforms of soluble complement receptor 1 |
| 07/24/2008 | WO2008089052A2 N-substituted glycine derivatives: hydroxylase inhibitors |
| 07/24/2008 | WO2008089008A2 Tetrahydrobiopterin prodrugs |
| 07/24/2008 | WO2008088047A1 Method for glycosylation of flavonoid |
| 07/24/2008 | WO2008088030A1 Composition for prevention or treatment of disease associated with thrombus or embolus |
| 07/24/2008 | WO2008087216A1 Use of platelet glycopeptide iiia epitopes in the treatment of immune thrombocytopenic purpura |
| 07/24/2008 | WO2008086750A1 Mixed fermentation method of callicarpa dichotoma (lour.) k. koch and edible fungus, prepared products via the method and uses thereof |
| 07/24/2008 | WO2008086739A1 Use of ursolic acid saponin, oleanolic acid saponin in preparation of increasing leucocyte and/or platelet medicine |
| 07/24/2008 | WO2008009635A3 Factor viia analogues with increased activity for treating thrombocytopenia |
| 07/24/2008 | WO2007132445A3 Use of non-catalytic form of heparanase and peptides thereof for reversing the anti-coagulant effects of heparinoids |
| 07/24/2008 | US20080176944 Elongase Genes and Uses Thereof |
| 07/24/2008 | US20080176916 A-amino-n-hydroxy-acetamide derivatives |
| 07/24/2008 | US20080176877 platelet lowering agent anagrelide especially 3-and 5-substituted analogues, with reduced potential for cardiovascular side-effects; imidazo[2,1-b]quinazolin-2-one derivatives; by inhibiting megakaryocytopoeisis; antiproliferative agents |
| 07/24/2008 | US20080176857 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors |
| 07/24/2008 | US20080176814 nonpeptidic inhibitors of cathepsin G; genetic diseases, degenerative diseases, DNA damages, neoplasia and/or skin diseases; DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing |
| 07/24/2008 | US20080176791 a mixture of antihemophilic factor, bulking agent selected from mannitol, glycine and alanine, stabilizer agents selected from sucrose, trehalose, raffinose and arginine, calcium chloride, sodium chloride and buffers, having storage stability |
| 07/24/2008 | US20080176789 comprising subjecting the materials to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix such as material is phenyl sepharose, to produce blood-coagulation factor XIII polypeptides precipitates, used for preventing bleeding and treating blood disorders |
| 07/24/2008 | US20080175878 Protease for activating clotting factor VII |
| 07/24/2008 | US20080175844 Activin-like receptor kinase immunoglobulin fusion for prevention and treatment of cell proliferative and vision defects; angiogenesis inhibitors |
| 07/24/2008 | US20080175831 Neuroprotection by blood flow stabilization |
| 07/24/2008 | US20080175820 Using vascular endothelial growth factor as wound healing agent; tissue engineering; regenerative medicine; wound healing agent |
| 07/24/2008 | CA2686816A1 Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder |
| 07/24/2008 | CA2675836A1 Composition for preventing or treating thrombus- or embolus-associated disease |
| 07/24/2008 | CA2675733A1 Method for glycosylation of flavonoid compounds |
| 07/24/2008 | CA2675134A1 Pterin analogs |
| 07/23/2008 | EP1947137A1 Biodegradable particle and method for producing the same |
| 07/23/2008 | EP1947101A1 Hydrazide compound and thrombopoietin receptor activator |
| 07/23/2008 | EP1946749A1 Anti-angionene compositions and methods of use |
| 07/23/2008 | EP1945634A1 Phenylenebisoxazolidine derivatives and their use as anticoagulants |
| 07/23/2008 | EP1945266A1 Methods of modulating apoptosis and platelet production using variants of cytochrome c |
| 07/23/2008 | EP1945032A2 Improved toleration iron supplement compositions |
| 07/23/2008 | EP1885347A4 Composition and method for treating nosebleeds |
| 07/23/2008 | EP1671949B1 Substituted Pyridinylamines |
| 07/23/2008 | EP1523988B1 Composition comprising radix codonopsis pilosulae and radix astragali for the treatment of acute lung injury |
| 07/23/2008 | EP1412361B1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 07/23/2008 | EP1372696B1 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 07/23/2008 | EP1272167B1 Ropinirole-containing hydrophilic/liphilic polymeric matrix dosage formulation |
| 07/23/2008 | EP1218369B1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 07/23/2008 | EP1181036B1 Pharmaceutical compositions of erythropoietin |
| 07/23/2008 | CN101228129A Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls |
| 07/23/2008 | CN101227904A Peritoneum protecting agent |
| 07/23/2008 | CN101225398A Technology for preparing active t-PA by procaryotic cells |
| 07/23/2008 | CN101224279A Medicine compound for treating urinary infection and preparing method thereof |
| 07/23/2008 | CN101224273A Preparing method of Jiaozhi soft capsule |
| 07/23/2008 | CN101224264A Chinese traditional medicine compounds for treating traumatic edema and preparing method thereof |
| 07/23/2008 | CN101224248A Medicine for treating heart, lung, liver, kidney hydrocele and preparing method thereof |
| 07/23/2008 | CN101224234A Medicine compounds and applications in treating or preventing blood vessel inflammation medicine |
| 07/23/2008 | CN101224226A Novel clinical uses of big nilgiri nettle |
| 07/23/2008 | CN101224223A Application of HCl in preparing medicine for treating gastritis, enteritis and vasculitis |
| 07/23/2008 | CN101224215A Uses of ursolic acid saponin and oleanolic acid saponin in preparing medicine for increasing white blood cell and/or blood platelet |
| 07/23/2008 | CN100404552C 因子Ⅷ多肽 Factor Ⅷ polypeptide |
| 07/23/2008 | CN100404539C Process for preparing amorphous form of a medicament - blood platelet coagulation inhibitor |
| 07/23/2008 | CN100404514C 2-substituted phenyl-4,4,5,5-tetramethyl-1,3,-dioxy imidazolines, their preparation and pharmaceutical use |
| 07/23/2008 | CN100404027C Carbamaid peroxide freeze dried formulation for injection, its preparation method and uses |
| 07/23/2008 | CN100404024C Synergestic combinations comprising renin inhibitor for cardiovascular diseases |
| 07/22/2008 | US7402682 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates |
| 07/22/2008 | US7402605 E.g., 17,17-propano-16-hydroxy-5-(4-ethoxycarbonylthiazol-2-yl)-9-oxo-1,2,3,4,20-pentanor-5-thia-8-azaprost-13-ene; EP2 and/or EP4 receptor agonist; immune disease; antiallergens; alopecia; dysmenorrhea; erectile dysfuncction; antiarthritic agents; liver, respiratory, vascular, urogenital disorder |
| 07/22/2008 | US7402595 JNK inhibitor |
| 07/22/2008 | US7402590 Spiroazacyclic compounds as monoamine receptor modulators |
| 07/22/2008 | US7402586 3-Benzylsulfonylamino-6-methyl-1-[(3-guanidinooxypropyl)aminocarbonylmethyl]-2-pyridinone trifluoroacetate; anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage |
| 07/22/2008 | US7402580 Polymerase inhibitors; antiischemic agents; brain disorders; cardiovascular disorders; antiinflammatory agents; antiarthritic agents; neurodegenerative agents; Alzheimer's disease; muscular disorders; antidiabetic agents; kidney disorders; viricides; anticancer agents; immunosuppressants |
| 07/22/2008 | US7402577 Androstane 17-beta-carboxamides as androgen receptor modulators |
| 07/22/2008 | US7402305 Comprises nucleotide sequences coding protein with antiproliferative and viricidal activity for use in treatment and prevention of cancer, nervous system, bone and autoimmune disorders |
| 07/22/2008 | US7402304 human granulocyte colony stimulating factor polypeptides having amino acid replacements in the sequence, used for treating hematopoietic, neurological or reproductive disorders |
| 07/22/2008 | CA2384418C Use of cytokines, cells, and mitogens to inhibit graft versus host disease |
| 07/22/2008 | CA2198916C Delivery of solid drug compositions |
| 07/22/2008 | CA1341577C Expression of biologically active factor xiii |
| 07/17/2008 | WO2008085119A1 New pyridine analogues viii 518 |
| 07/17/2008 | WO2008085118A1 Pyridine compounds and their use as p2y12 antagonists. |
| 07/17/2008 | WO2008085117A1 Pyridine compounds and their use as p2y12 antagonists. |
| 07/17/2008 | WO2008083678A2 Pharmaceutically active compounds |
| 07/17/2008 | WO2008065123A3 Polymorphic forms of deferasirox ( icl670a) |
| 07/17/2008 | WO2008065123A2 Polymorphic forms of deferasirox ( icl670a) |
| 07/17/2008 | WO2008057590A3 Methods and compositions for modulating tissue modeling |
| 07/17/2008 | WO2008024767A3 Method and composition for treating a fibrotic disorder |
| 07/17/2008 | WO2007121312A9 Trivalent chromium compounds, compositions and methods of use |
| 07/17/2008 | US20080171882 [(4S)-4-Methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride and [(4R)-4-methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride; chemical intermediates for enzyme inhibitors |
| 07/17/2008 | US20080171853 Formed via solid-state chemistry with 4-methylbenzylhydrylamine functionalized crosslinked polystyrene resin; deblocking, deprotecting; methylation |
| 07/17/2008 | US20080171781 Administering an extract of safflower seeds, p-coumaroyl, feruloyl or caffoyl serotonin, to suppress an increase of the pulse wave velocity and Augmentation Index, and decrease the systolic and mean blood pressure and pulse pressure; vascular ageing resistance; atherosclerosis; oral dosage; food additive |
| 07/17/2008 | US20080171773 A substantially pure enantiomer, (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; controlling factor Xa proteolytic activity to prevent thrombosis with out the risk factors affecting diabetics, heart conditions, etc |
| 07/17/2008 | US20080171756 e.g. N-{[4-hydroxy-6-oxo-2-phenyl-1-(phenylmethyl)-1,6-dihydro-5-pyrimidinyl]carbonyl}glycine; anemia caused by increasing the production of erythropoietin (Epo), ischemia, stroke, and cytoprotection |
| 07/17/2008 | US20080171060 Lymphocyte receptor peptide for use in prevention and treatment of viral infection, cell proliferative, cardiovascular and allergic disorders; enhancing cytokine production |